Relay Therapeutics IPO
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental technologies to develop targeted therapies. The company's protein motion platform and focus on oncology have positioned it as an innovative player in the precision medicine and cancer treatment space.
What We Know
Relay Therapeutics went public in July 2020 through a traditional IPO, raising approximately $400 million. The company trades on NASDAQ under the ticker symbol 'RLAY', with shares initially priced at $20 each, well above the expected range due to strong investor demand. Since going public, Relay has advanced multiple oncology programs through clinical trials and expanded its pipeline using its proprietary protein motion platform. The company's stock performance has reflected both progress in clinical development and broader biotech market sentiment, experiencing the volatility typical of clinical-stage biotechnology companies.
Frequently Asked Questions
Has Relay Therapeutics had an IPO?
Yes, Relay Therapeutics completed its IPO in July 2020, raising approximately $400 million. The precision medicines company trades publicly on NASDAQ under the ticker symbol 'RLAY'.
When is the Relay Therapeutics IPO date?
Relay Therapeutics already went public in July 2020, so there is no upcoming IPO date. The company completed its initial public offering and has been trading on NASDAQ for several years.
How can I buy Relay Therapeutics stock?
You can buy Relay Therapeutics stock through any brokerage platform as it trades on NASDAQ under ticker 'RLAY'. Shares are available for purchase during regular trading hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts